期刊文献+

奥氮平与氨磺必利治疗精神分裂症的对照疗效分析 被引量:3

Comparative Analysis of Olanzapine and Amisapride in the Treatment of Schizophrenia
下载PDF
导出
摘要 目的比较奥氮平与氨磺必利治疗精神分裂症的临床效果。方法选择医院84例精神分裂症患者,随机分为A、B两组。A组予以奥氮平治疗,B组予以氨磺必利治疗。对比两组治疗效果及不良反应发生状况。结果B组治疗总有效率与A组相比,无明显差异(P>0.05);B组嗜睡、泌乳与月经改变、体质量增加发生率分别为2.38%、7.14%、2.38%,明显低于A组的19.05%、23.81%、21.43%,两组之间存在显著差异(P<0.05)。结论在治疗精神分裂症方面,奥氮平和氨磺必利均可达到较好效果,但相较于奥氮平,氨磺必利的不良反应较小。 Objective To compare the clinical effects of olanzapine and amisapride in the treatment of schizophrenia.Methods Eighty-four patients with schizophrenia in our hospital were randomly divided into two groups:group A was treated with olanzapine and group B was treated with azepripine.The therapeutic effect and adverse reactions were compared between the two groups.Results There was no significant difference in the total effective rate between group B and group A(P>0.05).The incidence of drowsiness,lactation and menstrual changes,and weight gain in group B were 2.38%,7.14%,and 2.38%,respectively.There were 19.05%,23.81%,and 21.43%in group A,and there was a significant difference between the two groups(P<0.05).Conclusion Olanzapine and amisapride can achieve better results in the treatment of schizophrenia,but the adverse reactions of olanzapine are less than olanzapine.
作者 赵影 ZHAO Ying(Psychiatry Department,Changchun Sixth Hospital,Changchun Jilin 130000,China)
出处 《中国卫生标准管理》 2020年第3期82-83,共2页 China Health Standard Management
关键词 奥氮平 精神分裂症 氨磺必利 治疗效果 不良反应 安全性 olanzapine schizophrenia amisapride therapeutic effect adverse reactions safety
  • 相关文献

参考文献14

二级参考文献133

  • 1杜波,赵淑敏,田国庆,刘杰,张香云,张艳敏,张旭静,苏丽惠,韩彦超.阿立哌唑对精神分裂症患者血清催乳素及体重的影响[J].中国全科医学,2006,9(13):1065-1066. 被引量:15
  • 2沈渔邮.精神病学[M].5版.北京:人民卫生出版社,2010.
  • 3中华医学会精神科分会.中国精神障碍分类与诊断标准(CCMD-3)[M].第3版.济南:山东科学技术出版社,2001.
  • 4金卫东,马永春.循证精神病学[M].北京:人民军医出版社,2010:85-98.
  • 5Roth TL, Lubin FD, Sodhi M, et al. Epigenetic mechanisms in schizophrenia[J]. Biochimica Biophysica Acta (BBA)-General Subjects, 2009, 1790(9): 869-877.
  • 6World Health Organization. ICD-10: international statistical classification of diseases and related health problems[M]. 10th. Geneva: World Health Organization, 1992.
  • 7American Psychiatric Association. Diagnosis and statistical manual of mental disorders[M]. 5th. Arlington: American Psychiatric Publishing, 1994.
  • 8Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions[M]. Chichester, England: Wiley-Blackwell, 2008: 214-216.
  • 9Jindal KC, Singh GP, Munjal V. Aripiprazole versus olanzapine in the treatment of schizophrenia: A clinical study from India[J]. International Journal of Psychiatry in Clinical Practice, 2013, 17(1): 21-29.
  • 10De Hert M, Detraux J, Van Winkel R, et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs[J]. Nature Reviews Endocrinology, 2012, 8(2): 114-126.

同被引文献34

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部